Empa 25 mg (Tablet)

Title

• Empagliflozin 25 mg Tablet

Categories

• Medicine
• Diabetes management
• Cardiovascular health

Description

• Empagliflozin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus, and to reduce the risk of cardiovascular death in adult patients with type 2 diabetes mellitus and established cardiovascular disease. It is a sodium glucose co-transporter-2 (SGLT-2) inhibitor, which reduces renal absorption of glucose, leading to increased glucose excretion and contributing to reduced hyperglycemia, weight loss, and reduced blood pressure. The recommended dose of Empagliflozin is 10 mg once daily, taken in the morning, with or without food, and may be increased to 25 mg once daily in patients tolerating it. It is contraindicated in patients with a history of serious hypersensitivity reaction to Empagliflozin or any of its ingredients, severe renal impairment, end-stage renal disease, or dialysis.

Dosage and Administration

• 10 mg once daily in the morning, with or without food
• May be increased to 25 mg once daily in patients tolerating it

Function

• Improves glycemic control
• Reduces risk of cardiovascular death
• Reduces renal absorption of glucose
• Increases glucose excretion
• Contributes to weight loss
• Reduces blood pressure

Ingredients

• Empagliflozin

Drug Class

• Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors

Indications

• Adjunct to diet and exercise for improving glycemic control in adults with type 2 diabetes mellitus
• Reducing the risk of cardiovascular death in adult patients with type 2 diabetes mellitus and established cardiovascular disease

Pharmacology

• Sodium glucose co-transporter-2 (SGLT-2) inhibitor
• Reduces renal absorption of glucose
• Increases glucose excretion
• Reduces hyperglycemia
• Assists weight loss
• Reduces blood pressure

Recommended Dose

• 10 mg once daily, in the morning, with or without food
• May be increased to 25 mg once daily in patients tolerating it

Interactions

• Diuretics
• Insulin or Insulin Secretagogues
• Positive Urine Glucose Test
• Interference with 1,5-anhydroglucitol (1,5-AG) Assay

Contraindications

• History of serious hypersensitivity reaction to Empagliflozin or any of its ingredients
• Severe renal impairment
• End-stage renal disease
• Dialysis

Side Effects

• Urinary tract infections
• Female genital mycotic infections
• Dehydration
• Hypotension
• Weakness
• Dizziness
• Increased thirstiness

Pregnancy & Lactation

• Should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus
• Not recommended when breastfeeding

Precautions & Warnings

• Assessment of renal function recommended prior to initiation and periodically thereafter
• Not initiated in patients with an eGFR less than 45 ml/min/1.73 m^2

Overdose Effects

• Employ usual supportive measures
• Hemodialysis has not been studied for removal of Empagliflozin

Storage Conditions

• Keep in a cool & dry place (below 30°C)
• Protected from light & moisture
• Keep out of the reach of children

Chemical Structure

• Molecular Formula: C23H27ClO7
• Chemical Structure: (refer to image)
• Image link: https://medex.com.bd/storage/res/g-res-1275-empagliflozin-chemical-structure-Z3X0mrA6UvgM682Jgp8K.svg

Commonly Asked Questions

• What is Empa 25 mg Tablet?
• What is Empa 25 mg Tablet used for?
• Are there any pregnancy warnings?
• Are there any breast-feeding warnings?
• Does this affect kidney function?
• Does this affect liver function?
• Quick Tips

Related Brands

• Empa 10 mg (Tablet) - nipro-jmi-pharma-ltd